en
Scientific article
Open access
English

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies

Published inJournal of the European Academy of Dermatology and Venereology, vol. 34, no. 12, p. 2809-2820
Publication date2020
Abstract

Psoriatic arthritis (PsA) is a chronic, systemic immune-mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA that has been shown to improve dermatologic symptoms in patients with PsA.

Keywords
  • Adult
  • Arthritis
  • Psoriatic* / drug therapy
  • Double-Blind Method
  • Humans
  • Piperidines
  • Psoriasis* / drug therapy
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Quality of Life
  • Treatment Outcome
Citation (ISO format)
MEROLA, J F et al. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. In: Journal of the European Academy of Dermatology and Venereology, 2020, vol. 34, n° 12, p. 2809–2820. doi: 10.1111/jdv.16433
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0926-9959
120views
111downloads

Technical informations

Creation04/30/2021 3:38:00 PM
First validation04/30/2021 3:38:00 PM
Update time03/16/2023 1:19:27 AM
Status update03/16/2023 1:19:26 AM
Last indexation02/12/2024 1:30:19 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack